OnKure Therapeutics (NASDAQ:OKUR) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS

OnKure Therapeutics (NASDAQ:OKUR) released its quarterly earnings data on Wednesday. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.05, FiscalAI reports.

OnKure Therapeutics Trading Up 13.3%

OKUR stock traded up $0.34 during trading on Friday, reaching $2.87. 498,423 shares of the stock were exchanged, compared to its average volume of 270,234. The business has a 50 day moving average price of $2.80 and a 200-day moving average price of $3.59. OnKure Therapeutics has a 1 year low of $2.01 and a 1 year high of $5.38. The firm has a market capitalization of $115.81 million, a price-to-earnings ratio of -1.04 and a beta of 0.18.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on OKUR. Oppenheimer restated an “outperform” rating and issued a $14.00 price target on shares of OnKure Therapeutics in a research report on Friday, August 14th. HC Wainwright lowered their price objective on OnKure Therapeutics to $21.00 and set a “buy” rating on the stock in a research note on Monday, July 20th. Finally, Weiss Ratings upgraded OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, October 26th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $17.50.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company’s research is centered on small-molecule therapies designed to target cancer-driving transcription factors and related proteins that are difficult to address with conventional drug approaches.

Its lead product candidate, OKN4395, is an oral small-molecule inhibitor of the EP300/CBP bromodomains. The program is being investigated as a potential treatment for solid tumors, including in combination with immune checkpoint inhibitors such as pembrolizumab.